Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A7NZ
|
|||
| Former ID |
DIB011505
|
|||
| Drug Name |
CNTO-6785
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Rheumatoid arthritis [ICD-11: FA20] | Phase 2 | [1] | |
| Company |
Janssen research & development
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 17 receptor (IL17R) | Target Info | . | [2] |
| Interleukin-17 (IL17) | Target Info | . | [3] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Inflammatory bowel disease (IBD) | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Interleukin signaling pathway | |||
| Pathway Interaction Database | IL27-mediated signaling events | |||
| IL23-mediated signaling events | ||||
| WikiPathways | TCR Signaling Pathway | |||
| Allograft Rejection | ||||
| IL17 signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01909427) An Efficacy And Safety Study of CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov. 2015 Jan;14(1):11-2. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.